Cairo Pharmaceuticals results, Fiscal year 2025
Net profit, assets, equity and cash flow for Fiscal year 2025, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit444 millionEGP · +80.3% vs the same period a year earlier
Total assets2.03 billionEGP · +33.8% vs the same period a year earlier
Shareholders' equity1.05 billionEGP · +25.7% vs the same period a year earlier
Operating cash flow379 millionEGP · +44.1% vs the same period a year earlier
In short
- Cairo Pharmaceuticals's net profit for Fiscal year 2025 was about 444 million EGP, up +80.3% from 246 million EGP in Fiscal year 2024.
- Total assets at the end of Fiscal year 2025 were about 2.03 billion EGP, and shareholders' equity about 1.05 billion EGP.
- Operating cash flow for Fiscal year 2025 was positive at 379 million EGP.
Key lines against the same period a year earlier
This periodFiscal year 2024Change
Net profit444 million246 million+80.3%
Gross profit823 million533 million+54.4%
Total assets2.03 billion1.52 billion+33.8%
Total liabilities980 million683 million+43.6%
Shareholders' equity1.05 billion832 million+25.7%
Total liabilities and equity2.03 billion1.52 billion+33.8%
Operating cash flow379 million263 million+44.1%
Investing cash flow-118 million-232 million+48.9%
Financing cash flow-257 million-2.41 million−10564.5%
Net change in cash2.93 million28.9 million−89.9%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version.
Cairo Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy